Background: Rapid eye movement sleep behavior disorder and sleepiness precede
INTRODUCTION
Mutations in the LRRK2 (leucine-rich repeat kinase 2) gene, which codes for dardarine, may cause Parkinson disease (PD). 1, 2 The single mutation Gly2019Ser is associated with 3-6% of the familial PD forms and 2% of sporadic PD in Europe, [3] [4] [5] [6] and 37% of familial PD in Africa. Healthy carriers have been identified in families with LRRK2 mutations. The transmission is autosomal dominant, but the penetrance of parkinsonism varies from 28% at age 59 to 74% at age 79 for G2019S mutation. 7 Compared to idiopathic PD, the LRRK2 patients have a less marked, asymmetrical and tremor-predominant type of parkinsonism, with less frequent cognitive and olfactory deficits, but more frequent psychiatric symptoms (depression, anxiety, and irritability). [7] [8] [9] [10] Sleep problems are frequent in LRRK2-associated PD, as 69% of 268 mutated patients complain of disturbed sleep (single question). 7 Healthy mutation carriers report shorter sleep time than non-carriers. 11 Sleep disturbances are also prevalent in idiopathic PD, including insomnia, REM sleep behavior disorder (RBD, a condition characterized by violent, enacting dreams plus REM sleep without atonia), 12 sleepiness, restless legs syndrome and periodic limb movements. 13 Notably, sleepiness and RBD can predate the onset of parkinsonism by several years. [14] [15] [16] [17] The presence of RBD in the first years of PD confers a high risk of later developing dementia. 18 To date, no study has systematically investigated the sleep phenotype associated with LRRK2 mutations using formal sleep monitoring. Because healthy carriers may have sleep markers predicting phenoconversion to parkinsonism, we systematically studied the video-polysomnography in patients with LRRK2-associated PD vs. patients with idiopathic PD, and in healthy LRRK2 mutation carriers vs.
healthy controls.
METHODS
We invited all patients with LRRK2 mutations and their relatives on the list of the French PD Genetics Network to participate in a phenotype study. Patients had defined parkinsonism 19 and a mutation in the LRRK2 gene (G2019S, R1441H).
Healthy LRRK2 mutation carriers were selected among their first-degree relatives.
They carried the gene mutation (but ignored it), and had no sign of neurological disorder. Patients with idiopathic PD matched for age, sex, and disease duration were selected from another program, with no selection regarding sleep disturbances. 20 They met PD criteria 19 and had a sporadic disease. Healthy controls included the non-mutated first-degree healthy relatives of LRRK2 patients (n=5) and healthy controls (n=7), matched for age and sex with healthy LRRK2 mutations carriers, and examined by neurologists to rule out any neurological disorder. All participants signed an informed consent for the study, which was approved by the ethical committee.
The motor disability was evaluated of at the time of the best effect of the dopaminergic treatment, using the Unified PD rating scale-III. 21, 22 All participants and bed partners were interviewed about agitating nightmares and completed the Epworth sleepiness scale. 23 They underwent a video-polysomnography including EEG, electro-oculography, nasal pressure and respiratory efforts, electrocardiography, oximetry, chin and bilateral legs EMG, and infrared video-sound monitoring. The recordings were visually scored blinded to the neurological and genetic status, using international rules. 24 The autonomic activity was measured using an analysis of the R-R cardiac interval on the EKG during the night (Medatec®, France). The mean, standard deviation and coefficient of variation (the ratio of the SD to the mean, an indicator of signal variability) of heart rate was obtained in 5 minutes 
RESULTS
There were two patients with a mutation in the R1441H part of the LRRK2 gene and eight patients and four healthy carriers with a mutation in the G2019S part of the LRRK2 gene. The body mass index and scores on the Epworth sleepiness scale were higher in the LRRK2 healthy carriers than in the control groups ( Table 1 ). The motor disability and dopaminergic treatment were not different in the LRRK2-associated PD than in the with idiopathic PD groups. The sleep measures were not different between groups (Table 2 ). There was no REM sleep without atonia in LRRK2-mutated subjects independent of whether they already had PD. None of the subjects with LRRK2 mutations had "any" tonic or phasic enhanced chin muscle activity during more than 18% of REM sleep, while this was the case in 13 (65%) patients with idiopathic PD, of whom only 7 took an antidepressant. The remaining 6 patients with PD taking an antidepressant had no RBD or REM sleep without atonia.
The percentages of phasic and tonic REM sleep without atonia were higher in idiopathic than in LRRK2-associated PD groups. Eventually, when combining clinical and polysomnographic RBD criteria, none of the 14 subjects with LRRK2 mutations had a defined RBD, vs. 9 (45%) patients with idiopathic PD (4 patients with idiopathic PD had isolated REM sleep without atonia). There were behaviors during REM sleep on the video analysis in 8 patients with idiopathic PD and in no patient with a LRRK2 mutation. The periodic leg movement index and associated arousal index, as well as the frequency of abnormal periodic leg movements 26 were not different between groups. The analysis of the variability of the R-R cardiac interval did not yield any difference between groups, whatever the sleep stage (Supplemental Table) .
DISCUSSION
The 14 subjects with LRRK2 mutations studied with sleep tests had no major sleep changes when compared with matched controls (healthy controls or patients with idiopathic PD). Notably, none of the subjects with LRRK2 mutations had any defined RBD or REM sleep without atonia (a preclinical stage of RBD). Patients with LRRK2-associated PD had a variability of the heart rate during wake and sleep similar to the other groups' variability.
To the best of our knowledge, there has not been any previous systematic study of sleep structure and motor activity in subjects with LRRK2 mutations, but only questionnaire-based studies. 7, 11 We did not find an abnormal subjective sleepiness in 10 patients with LRRK2-associated PD, in accordance with previous data. 10 In this context, the increased level of sleepiness in our LRRK2 mutation healthy carriers (but not in those with PD) may correspond to random fluctuation, rather than to a robust early marker of neurodegeneration. However, a limitation here is that we did not perform multiple sleep latency tests, which may detect an abnormal propensity to fall asleep in some patients with PD denying any subjective sleepiness.
27
Reduced or fragmented sleep was frequently reported on questionnaires among patients with LRRK2 mutations, 7 but there was no significant difference with patients with idiopathic PD when the sleep disturbances were stratified by disease duration or by mutation, suggesting that parkinsonism (and its motor consequences during the night, including difficulties turning in bed, readjusting blankets, urinating, pain and tremor) rather than the LRRK2 gene causes interrupted sleep. Therefore, patients with LRRK2 mutations and subclinical parkinsonism report the same usual nighttime sleep time than non-mutation carriers. 10 The objective measures of sleep time and fragmentation in our study support this view, as sleep latencies, total sleep time, sleep efficacy, and arousal index were not different in subjects with LRRK2 mutations than in matched controls.
The absence of defined RBD and REM sleep without atonia in 14 subjects with LRRK2 mutations independent of whether they were presymptomatic or symptomatic is a strong finding in our cohort. In contrast, RBD was frequent (45%) in patients with idiopathic PD, as it is the case in PD. 28, 29 This result may rule out the concept of concomitant RBD in presymptomatic LRRK2-associated PD, at least around age 40, and suggests that RBD, if present in some patients with LRRK2 mutations as occasionally mentioned using non-systematic sleep studies in a large cohort of 268 patients, 7 is a rare occurrence. Similarly, among 32 LRRK2 carriers with mild parkinsonism, a single mutated patient with dream-enacted behavior was suspected of clinical RBD. 11 Nevertheless, one may keep in mind that dream-enacted behavior may also correspond to adult sleepwalking 30 or confusional arousals caused by apnea, sleep deprivation or drugs. 31 As a consequence, robust diagnostic criteria, including frequent behaviors plus video-polysomnography with REM sleep without atonia are mandatory for defining RBD. Eventually, patients with frequent dreamenacted behaviors in cohorts of mutation carriers should be studied with videopolysomnography to determine whether RBD is definitively absent at the preparkinsonism stage and instead develops with age (when penetrance increases) or longer parkinsonism. In contrast, despite the fact that LRRK2 patients had a similar disease course and motor disability than those with idiopathic PD, they seemed to be protected from RBD. This result, together with the better autonomic function during REM sleep in patients with LRRK2 than with idiopathic PD (whereas it is altered in idiopathic RBD), 25 support the concept that LRRK2-associated PD is a unique subtype of PD. Notably, LRRK2 patients have a lower risk of developing dementia than patients with idiopathic PD. [7] [8] [9] [10] Because RBD strongly predicts dementia in idiopathic PD, 18 and is associated with cholinergic loss, 32 one may wonder whether absent RBD and rare dementia in LRRK2 patients may result from a similar pathophysiology, e.g., a lower loss of cholinergic neurons. RBD seems to be rare in some other genetic parkinsonisms, including patients with two parkin mutations, 33 and a family with PINK1-associated parkinsonism. 34 However, it was found in two brothers with DJ-1 mutations. 35 Plus, idiopathic RBD and the risk of earlier conversion to synucleinopathy have been recently associated with a subset of PDassociated genes. 36 The main limitation of our study is the limited sample size (especially the LRRK2 healthy carriers). However, the LRRK2 mutation is a rare genetic mutation mostly present in North Africa: patients have to travel to France for the study. We tried to circumvent this bias by matching the LRRK2 groups with larger control groups.
The sample size is counterbalanced by the objective findings obtained during videopolysomnography, a sensitive procedure difficult to perform in large cohorts.
In conclusion, no LRRK2-specific sleep phenotype was identified in this systematic study. Instead, the sleep structure in LRRK2-associated PD parallels that of idiopathic PD, except for absent RBD. Since no presymptomatic RBD was found in patients with LRRK2 mutations, RBD cannot be used as surrogate, early markers of neurodegeneration in future neuroprotective interventions in LRRK2 healthy carriers.
